
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its clinical pipeline, underscoring significant progress in its precision oncology programs. The …
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements Read More